The BiTE (Bispecific T‐Cell engager) platform: Development and future potential of a targeted immuno‐oncology therapy across tumor types

Phase I study of pasotuxizumab (AMG 212/BAY 2010112), a PSMA-targeting BiTE (Bispecific T-cell Engager) immune therapy for metastatic castration-resistant prostate cancer (mCRPC).

(2020) Horst-Dieter Hummel et al.   JOURNAL OF CLINICAL ONCOLOGY

Anti–B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma

(2020) Max S. Topp et al.   JOURNAL OF CLINICAL ONCOLOGY

Preclinical evaluation of AMG 160, a next-generation bispecific T cell engager (BiTE) targeting the prostate-specific membrane antigen PSMA for metastatic castration-resistant prostate cancer (mCRPC).

(2019) Julie Bailis et al.   JOURNAL OF CLINICAL ONCOLOGY

Neurotoxicity associated with cancer immunotherapy

(2019) Claire Perrinjaquet et al.   CURRENT OPINION IN NEUROLOGY

Bispecific Antibodies in the Treatment of Hematologic Malignancies

(2019) Johannes Duell et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

DLL 3 regulates the migration and invasion of small cell lung cancer by modulating Snail

(2019) Megumi Furuta et al.   CANCER SCIENCE

CAR-T efficacy: is conditioning the key?

(2019) Sattva S. Neelapu   BLOOD

Phase 1 study of pasotuxizumab (BAY 2010112), a PSMA-targeting Bispecific T cell Engager (BiTE) immunotherapy for metastatic castration-resistant prostate cancer (mCRPC).

(2019) Horst-Dieter Hummel et al.   JOURNAL OF CLINICAL ONCOLOGY

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

(2019) Noopur Raje et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mucin 17 inhibits the progression of human gastric cancer by limiting inflammatory responses through a MYH9-p53-RhoA regulatory feedback loop

(2019) Bing Yang et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

A Review of Efficacy and Safety of Checkpoint Inhibitor for the Treatment of Acute Myeloid Leukemia

(2019) Dan Liao et al.   Frontiers in Pharmacology

An Individualized Risk Mitigation Approach for Safety: Experience from the Mosunetuzumab (CD20/CD3 Bispecific Antibody) Development Program in Relation to Neurotoxicity Risk

(2019) Catherine Diefenbach et al.   BLOOD

ATIM-49 (LTBK-01). AMG 596, A NOVEL ANTI-EGFRVIII BISPECIFIC T CELL ENGAGER (BITE®) MOLECULE FOR THE TREATMENT OF GLIOBLASTOMA (GBM): PLANNED INTERIM ANALYSIS IN RECURRENT GBM (RGBM)

(2019) Mark A Rosenthal et al.   NEURO-ONCOLOGY

Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia

(2018) Nicola Gökbuget et al.   BLOOD

Investigational CD33-targeted therapeutics for acute myeloid leukemia

(2018) Roland B. Walter   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation

(2018) Colin E. Correnti et al.   LEUKEMIA

The application of CAR-T cell therapy in hematological malignancies: Advantages and challenges

(2018) Zijun Zhao et al.   Acta Pharmaceutica Sinica B

Checkpoint Inhibition in Myeloma: Opportunities and Challenges

(2018) Federica Costa et al.   Frontiers in Immunology

Immuno-Oncology: Emerging Targets and Combination Therapies

(2018) Henry T. Marshall et al.   Frontiers in Oncology

Benefit–Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

(2018) Anthony Stein et al.   DRUG SAFETY

Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome–Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study

(2017) Giovanni Martinelli et al.   JOURNAL OF CLINICAL ONCOLOGY

New development in CAR-T cell therapy

(2017) Zhenguang Wang et al.   Journal of Hematology & Oncology

Immunotherapy in hematologic malignancies: past, present, and future

(2017) Annie Im et al.   Journal of Hematology & Oncology

Checkpoint inhibitors in hematological malignancies

(2017) Chi Young Ok et al.   Journal of Hematology & Oncology

CD19 Isoforms Enabling Resistance to CART-19 Immunotherapy Are Expressed in B-ALL Patients at Initial Diagnosis

(2017) Jeannette Fischer et al.   JOURNAL OF IMMUNOTHERAPY

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

(2017) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment

(2017) E. Mejstríková et al.   Blood Cancer Journal

Cancer immunotherapy: the beginning of the end of cancer?

(2016) Sofia Farkona et al.   BMC Medicine

Harnessing T cells to fight cancer with BiTE®antibody constructs - past developments and future directions

(2016) Matthias Klinger et al.   IMMUNOLOGICAL REVIEWS

Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

(2016) Arend von Stackelberg et al.   JOURNAL OF CLINICAL ONCOLOGY

A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo

(2016) S Hipp et al.   LEUKEMIA

CD33 is frequently expressed in cases of myelodysplastic syndrome and chronic myelomonocytic leukemia with elevated blast count

(2016) David Sanford et al.   LEUKEMIA & LYMPHOMA

Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer

(2016) Kaichao Feng et al.   Science China-Life Sciences

Immune checkpoint blockade in hematologic malignancies

(2015) P. Armand   BLOOD

Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma

(2015) Nabil Ahmed et al.   JOURNAL OF CLINICAL ONCOLOGY

The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment

(2015) G. K. Pennock et al.   ONCOLOGIST

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy

(2013) Matthew D. Vesely et al.   Annals of the New York Academy of Sciences

CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330

(2013) C. Krupka et al.   BLOOD

Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML

(2013) G. S. Laszlo et al.   BLOOD

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

(2013) Stephan A. Grupp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Regression of Human Prostate Cancer Xenografts in Mice by AMG 212/BAY2010112, a Novel PSMA/CD3-Bispecific BiTE Antibody Cross-Reactive with Non-Human Primate Antigens

(2012) M. Friedrich et al.   MOLECULAR CANCER THERAPEUTICS

CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2005-2009

(2012) T. A. Dolecek et al.   NEURO-ONCOLOGY

Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma

(2011) C. U. Louis et al.   BLOOD

Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab

(2011) Dirk Nagorsen et al.   EXPERIMENTAL CELL RESEARCH

Bispecific T-Cell Engaging Antibodies for Cancer Therapy

(2009) P. A. Baeuerle et al.   CANCER RESEARCH

Claudin-18 Splice Variant 2 Is a Pan-Cancer Target Suitable for Therapeutic Antibody Development

(2008) U. Sahin et al.   CLINICAL CANCER RESEARCH